Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study
More about Open Access at the CrickAuthors list
R Kurzrock DW Bowles H Kang F Meric-Bernstam J Hainsworth DR Spigel R Bose H Burris CJ Sweeney MS Beattie S Blotner K Schulze V Cuchelkar Charles SwantonAbstract
Systemic therapy options for salivary cancers are limited. MyPathway (NCT02091141), a phase IIa study, evaluates targeted therapies in non-indicated tumor types with actionable molecular alterations. Here, we present the efficacy and safety results for a subgroup of MyPathway patients with advanced salivary gland cancer (SGC) matched to targeted therapies based on tumor molecular characteristics.
Journal details
Journal Annals of Oncology
Volume 31
Issue number 3
Pages 412-421
Available online
Publication date
Full text links
Publisher website (DOI) 10.1016/j.annonc.2019.11.018
Figshare View on figshare
Europe PubMed Central 32067683
Pubmed 32067683